PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-57.23%
Revenue decline while Healthcare median is 0.00%. Seth Klarman would investigate if market share loss is temporary.
No Data
No Data available this quarter, please select a different quarter.
-57.23%
Gross profit decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
-15.08%
R&D reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive implications.
-0.47%
G&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.89%
Operating expenses reduction while Healthcare median is 4.85%. Seth Klarman would investigate advantages.
-10.89%
Total costs reduction while Healthcare median is 6.05%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
3.20%
D&A growth exceeding 1.5x Healthcare median of 1.91%. Jim Chanos would check for overinvestment.
5.74%
EBITDA change of 5.74% versus flat Healthcare. Walter Schloss would verify quality.
-120.42%
EBITDA margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
5.53%
Income change of 5.53% versus flat Healthcare. Walter Schloss would verify quality.
-120.91%
Operating margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
3.85%
Other expenses change of 3.85% versus flat Healthcare. Walter Schloss would verify control.
5.62%
Income change of 5.62% versus flat Healthcare. Walter Schloss would verify quality.
-120.69%
Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
5.62%
Income change of 5.62% versus flat Healthcare. Walter Schloss would verify quality.
-120.69%
Net margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
13.79%
EPS change of 13.79% versus flat Healthcare. Walter Schloss would verify quality.
13.79%
Diluted EPS change of 13.79% versus flat Healthcare. Walter Schloss would verify quality.
10.10%
Share count reduction below 50% of Healthcare median of 0.12%. Jim Chanos would check for issues.
10.10%
Diluted share reduction below 50% of Healthcare median of 0.06%. Jim Chanos would check for issues.